Cargando…

A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib

In non-small cell lung cancer (NSCLC), driver gene alterations, such as EGFR, ALK, MET, and ROS1, are usually mutually exclusive. Few clinical cases with co-existing ROS1 fusion and de-novo MET amplification have been reported. In addition, the efficacy of crizotinib in Chinese patients with driver...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, You-cai, Wang, Wen-xian, Xu, Chun-wei, Zhuang, Wu, Song, Zheng-bo, Du, Kai-qi, Chen, Gang, Lv, Tang-feng, Song, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301800/
https://www.ncbi.nlm.nih.gov/pubmed/30095326
http://dx.doi.org/10.1080/15384047.2018.1491506
_version_ 1783381865342697472
author Zhu, You-cai
Wang, Wen-xian
Xu, Chun-wei
Zhuang, Wu
Song, Zheng-bo
Du, Kai-qi
Chen, Gang
Lv, Tang-feng
Song, Yong
author_facet Zhu, You-cai
Wang, Wen-xian
Xu, Chun-wei
Zhuang, Wu
Song, Zheng-bo
Du, Kai-qi
Chen, Gang
Lv, Tang-feng
Song, Yong
author_sort Zhu, You-cai
collection PubMed
description In non-small cell lung cancer (NSCLC), driver gene alterations, such as EGFR, ALK, MET, and ROS1, are usually mutually exclusive. Few clinical cases with co-existing ROS1 fusion and de-novo MET amplification have been reported. In addition, the efficacy of crizotinib in Chinese patients with driver co-existing alterations is uncertain. A 65-year-old female was diagnosed with lung adenocarcinoma metastatic to the brain. She had sufficient tumor tissue for detection of the target gene; however, common driver gene mutations, such as EGFR-wild and ALK-negative, were not initially detected. The patient was ultimately shown to have both ZCCHC8-ROS1 and de-novo MET gene amplification through next-generation sequencing with sensitivity to the targeted therapy of crizotinib. Unfortunately, the progression-free survival was only 6 months in length. We report here the first patient with co-existing ROS1 fusion and de-novo MET amplification to receive crizotinib in China. Treatment of our patient was effective with targeted therapy based on a precise diagnosis. Advanced or metastatic NSCLC patients with co-existing ROS1 fusion and de-novo MET amplification are sensitive to crizotinib. These uncommon driver gene mutations may be missed using the current first-generation detection assay. We must be aware of the incidence of concomitant ROS1 fusion and de-novo MET amplification because NSCLC patients could benefit from targeted therapy.
format Online
Article
Text
id pubmed-6301800
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-63018002019-01-07 A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib Zhu, You-cai Wang, Wen-xian Xu, Chun-wei Zhuang, Wu Song, Zheng-bo Du, Kai-qi Chen, Gang Lv, Tang-feng Song, Yong Cancer Biol Ther Bedside to Bench Report In non-small cell lung cancer (NSCLC), driver gene alterations, such as EGFR, ALK, MET, and ROS1, are usually mutually exclusive. Few clinical cases with co-existing ROS1 fusion and de-novo MET amplification have been reported. In addition, the efficacy of crizotinib in Chinese patients with driver co-existing alterations is uncertain. A 65-year-old female was diagnosed with lung adenocarcinoma metastatic to the brain. She had sufficient tumor tissue for detection of the target gene; however, common driver gene mutations, such as EGFR-wild and ALK-negative, were not initially detected. The patient was ultimately shown to have both ZCCHC8-ROS1 and de-novo MET gene amplification through next-generation sequencing with sensitivity to the targeted therapy of crizotinib. Unfortunately, the progression-free survival was only 6 months in length. We report here the first patient with co-existing ROS1 fusion and de-novo MET amplification to receive crizotinib in China. Treatment of our patient was effective with targeted therapy based on a precise diagnosis. Advanced or metastatic NSCLC patients with co-existing ROS1 fusion and de-novo MET amplification are sensitive to crizotinib. These uncommon driver gene mutations may be missed using the current first-generation detection assay. We must be aware of the incidence of concomitant ROS1 fusion and de-novo MET amplification because NSCLC patients could benefit from targeted therapy. Taylor & Francis 2018-08-10 /pmc/articles/PMC6301800/ /pubmed/30095326 http://dx.doi.org/10.1080/15384047.2018.1491506 Text en © 2018 The Author(s). Published by Taylor & Francis. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Bedside to Bench Report
Zhu, You-cai
Wang, Wen-xian
Xu, Chun-wei
Zhuang, Wu
Song, Zheng-bo
Du, Kai-qi
Chen, Gang
Lv, Tang-feng
Song, Yong
A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
title A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
title_full A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
title_fullStr A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
title_full_unstemmed A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
title_short A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
title_sort novel co-existing zcchc8-ros1 and de-novo met amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
topic Bedside to Bench Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301800/
https://www.ncbi.nlm.nih.gov/pubmed/30095326
http://dx.doi.org/10.1080/15384047.2018.1491506
work_keys_str_mv AT zhuyoucai anovelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT wangwenxian anovelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT xuchunwei anovelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT zhuangwu anovelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT songzhengbo anovelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT dukaiqi anovelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT chengang anovelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT lvtangfeng anovelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT songyong anovelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT zhuyoucai novelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT wangwenxian novelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT xuchunwei novelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT zhuangwu novelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT songzhengbo novelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT dukaiqi novelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT chengang novelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT lvtangfeng novelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib
AT songyong novelcoexistingzcchc8ros1anddenovometamplificationdualdriverinadvancedlungadenocarcinomawithagoodresponsetocrizotinib